Son güncelleme :
19/11/2024
Antibiyotik   Netilmicin sulfate  
Enjeksiyon
Aerosol
Çözeltilerin stabilitesi Karışımlardaki stabilitesi Stabiliteyi etkileyen faktörler Uyumluluk Uygulama yöntemi Kaynaklar pdf
   Kimyasal yapı   

Ticari isim   Ticari isim     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Bactob Hindistan
Beltob Hindistan
Bramicil İtalya
Brulamycin Macaristan
Eltol Hindistan
Fytobra Hindistan
Gernebcin Almanya
Komitub Hindistan
Nebcin Avustralya, Birleşik Arap Emirlikleri, Büyük Britanya, Mısır, Suudi Arabistan, yeni Zelanda, Yunanistan
Nebcina Danimarka, Fas, İsveç, Norveç
Nebcine Fas
Nebicina İtalya
Netilyn Finlandiya, İsveç
Netromicina Portekiz
Netromicine Fransa
Netromycine Polonya, rusça, Türkiye, Yunanistan
Nettacin İtalya
Obracin Belçika, Hollanda, İsviçre, Lüksemburg
Tobra Almanya
Tobra Alex Mısır
Tobra Day yeni Zelanda
Tobra Gobens İspanya
Tobracin Mısır
Tobradistin İspanya
Tobramicina İspanya, İtalya, Portekiz, Venezuela
Tobramina Brezilya
Tobramycin Almanya, Amerika Birleşik Devletleri, Avustralya, Büyük Britanya, İrlanda, Kanada, Norveç, Suudi Arabistan
Tobramycine Belçika, Hollanda, Kanada, Lüksemburg
Tobrasix Avusturya
Tobrazid Almanya
Tomycin Finlandiya
Zetamicin İtalya
Kaynaklar   Enjeksiyon    Kaynaklar : Netilmicin sulfate  
tip yayın
3 Dergi Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59 Dergi Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
84 Dergi Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 Dergi Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 Dergi Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Dergi Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 Dergi Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Dergi Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Dergi Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
289 Dergi Jim LK.
Physical and chemical compatibility of intravenous ciprofloxacin with other drugs.
Ann Pharmacotherapy 1993 ; 27: 704-707.
299 Dergi Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Dergi Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Dergi Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Dergi Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
335 Dergi Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
367 Dergi Thompson DF, Allen LV, Desai SR, Rao PS.
Compatibility of furosemide with aminoglycoside admixtures.
Am J Hosp Pharm 1985 ; 42: 116-119.
421 Dergi Foley PT, Bosso JA, Bair JN, Townsend RJ.
Compatibility of clindamycin phosphate with cefotaxim sodium or netilmicin sulfate in small-volume admixtures.
Am J Hosp Pharm 1985 ; 42: 839-843.
492 Dergi Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
905 Dergi Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Dergi Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
958 Dergi Vervloet E, Lammers J, Tan LSL, Van Mourik CH, Rots M.
Netilmicin sulfate stability in combinaison with metronidazole or ranitidine hydrochloride in NaCl 0.9% infusion.
Ann Pharmacotherapy 1990 ; 24: 440-442.
999 Dergi Watson D.
Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution.
JPEN 1985 ; 9: 220-224.
1022 Dergi Hutchinson SMW.
Heparin and aminoglycosides instability.
Drug Intell Clin Pharm 1986 ; 20: 886.
1035 Dergi Bisaillon S, Sarrazin R.
Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion.
J Parenter Sci Technol 1983 ; 37: 129-132.
1200 Dergi Chaudry IA, Bruey KP, Hurlburt LE, Oden EM.
Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives.
Am J Hosp Pharm 1981 ; 38: 1737-1742.
1236 Dergi Kuhn RJ, Nahata MC.
Stability of netilmicin sulfate in admixtures with calcium gluconate and aminophylline.
Am J Hosp Pharm 1986 ; 43: 1241-1242.
1410 Dergi Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Dergi Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Dergi Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1754 Dergi Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1925 Dergi Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1929 Dergi Rigge DC, Jones MF.
Shelf lives of aseptically prepared medicines - stability of netilmicin injection in polypropylene syringes.
J Pharm Biomed Anal 2004 ; 35: 1251-1256.
2296 Laboratuar Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017
3522 Laboratuar Flucloxacillin - Summary of Product Characteristics.
Actavis 2013
3523 Laboratuar Ceftriaxone (Rocephin®) - Summary of Product Characteristics.
Roche 2018
3526 Laboratuar Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010
3527 Laboratuar Amoxicillin (Amoxil®) – Summary of Product Characteristics
Glaxo Smith Kline 2018
3540 Laboratuar Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3543 Laboratuar Ceftazidime – Summary of Product Characteristics
Wockhardt 2013
3544 Laboratuar Cefoperazone (Cefobid®) - Summary of Product Characteristics
Pfizer 2006
3545 Laboratuar Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit
Mylan SAS 2009
3546 Laboratuar Cefamandole Flavelab - Résumé des caractéristiques du produit
Panpharma SA 2007
3548 Laboratuar Cefepime (Maxipime®) - Summary of Product caracteristics.
Bristol Myers Squibb 2007
3578 Laboratuar Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011
3586 Laboratuar Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit
Actavis France 2010
3587 Laboratuar Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics
GlaxoSmithKline 2014
3594 Laboratuar Metronidazole (Flagyl®) - Summary of Product Characteristics
Zentiva 2013
3644 Laboratuar Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3656 Laboratuar Teicoplanine (Targocid®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2014
3674 Laboratuar Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3687 Laboratuar Cefuroxime sodium - Summary of Product Characteristics
Stravencon 2013
3883 Laboratuar Ceftazidime - Résumé des caractéristiques du produit
Arrow 2016

  Mentions Légales